This growth was dominated by five blockbuster pain drugs: OxyContin, Lyrica, Cymbalta, Celebrex and Lidoderm. The top five pain medication companies accounted for 76.1 percent of the global market and Pfizer was the market leader, with $6.4 billion in sales in 2010.
Chronic pain is the most studied indication for these medications, but there is strong interest in neuropathic pain and acute pain. More than 200 pain drugs are in clinical development.
Read the Reportlinker release on the global pain medication market.
Related Articles on Pain Medications:
Half of Patients Prescribed Opioids Still Taking Them Five Years Later
Study: Addiction to Meds Common for Chronic Pain Patients
Florida Delays Prescription Pad Requirement in Pill Mill Law
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.